Hint mode is switched on Switch off
Cbonds API
Integrate prices, fundamentals and corporate actions into your workflow

Get Global Stock Data via API

  • Prices & history
  • Fundamentals
  • Dividends & corporate actions

Athira Pharma, ordinary share
ATHA, US04746L1044

FIND, SAVE & TRACK INVESTMENTS WITH CBONDS WATCHLIST

With Cbonds Watchlist you can always stay updated on your investments to make conscious decisions!

Watchlist
You need to request access
Add a stock to WL
Choose all Reset all
Save Close
LeonaBio, сountry — USA
18/09/2025 stock stopped trading due to affiliation to LeonaBio, ordinary share
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Latest quotes

Try in 7-days Trial access

  • Get full online access to the database
  • Use our powerful bond screener
  • Track bond prices from 400+ sources
  • Smart Portfolio Monitoring
Unlock Data
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Issuer

Profile
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The ...
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    LeonaBio, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Other stocks and deposit receipts

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ATHA
  • Placement
    18.09.2020
  • Lock up period
    180
  • Number of papers
    12,000,000
  • Volume of raised funds
    204 mln USD
  • Raised funds in USD
    -
  • Placement share
    38.94%
  • Final placement price
    17 USD
  • Price change since placement date
    -100%
  • By capitalization
    523.93 mln USD
Other placements of the issuer
Other placements of the issuer
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ATHA
  • Placement
    21.01.2021
  • Lock up period
    180
  • Number of papers
    4,000,000
  • Volume of raised funds
    90 mln USD
  • Raised funds in USD
    -
  • Placement share
    11.4%
  • Final placement price
    22.5 USD
  • Price change since placement date
    -100%
  • By capitalization
    789.47 mln USD

Indicators

IFRS/US GAAP reports

  • 2026

  • 2025

  • 2024

  • 2023

  • 2022

  • 2021

  • 2020

    • News

    All organization news

    Holders

    Industry Leaders

    Registration is required to get access.